Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer

Christine Mall, Gail D. Sckisel, David A. Proia, Annie Mirsoian, Steven K. Grossenbacher, Chien Chun Steven Pai, Mingyi Chen, Arta M. Monjazeb, Karen Kelly, Bruce R. Blazar, William J. Murphy

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Monoclonal antibodies (mAbs) targeting coinhibitory molecules such as PD-1, PD-L1 and CTLA-4 are increasingly used as targets of therapeutic intervention against cancer. While these targets have led to a critical paradigm shift in treatments for cancer, these approaches are also plagued with limitations owing to cancer immune evasion mechanisms and adverse toxicities associated with continuous treatment. It has been difficult to reproduce and develop interventions to these limitations preclinically due to poor reagent efficacy and reagent xenogenecity not seen in human trials. In this study, we investigated adverse effects of repeated administration of PD-1 and PD-L1 mAbs in the murine 4T1 mammary carcinoma model. We observed rapid and fatal hypersensitivity reactions in tumor bearing mice within 30–60 min after 4–5 administrations of PD-L1 or PD-1 mAb but not CTLA-4 antibody treatment. These events occurred only in mice bearing the highly inflammatory 4T1 tumor and did not occur in mice bearing non-inflammatory tumors. We observed that mortality was associated with systemic accumulation of IgG1 antibodies, antibodies specific to the PD-1 mAb, and accumulation of Gr-1high neutrophils in lungs which have been implicated in the IgG mediated pathway of anaphylaxis. Anti-PD-1 associated toxicities were alleviated when PD-1 blockade was combined with the therapeutic HSP90 inhibitor, ganetespib, which impaired immune responses toward the xenogeneic PD-1 mAb. This study highlights a previously uncharacterized fatal hypersensitivity exacerbated by the PD-1/PD-L1 axis in the broadly used 4T1 tumor model as well as an interesting relationship between this particular class of checkpoint blockade and tumor-dependent immunomodulation.

Original languageEnglish (US)
Issue number2
StatePublished - Feb 1 2016

Bibliographical note

Funding Information:
This work has been supported by the National Institutes of Health (NIH) grant R01CA095572 and R01 CA72669. We would also like to acknowledge the UC Davis Comprehensive Cancer Center Shared Resources Flow Cytometry Core which was used for all flow cytometry data acquisition and is funded by the UC Davis Comprehensive Cancer Center Support Grant (CCSG, NCI P30CA093373).

Publisher Copyright:
© 2016 Taylor & Francis Group, LLC.


  • 4T1
  • Anaphylaxis
  • PD-1
  • PD-L1
  • breast cancer
  • checkpoint blockade
  • hypersensitivity
  • neutrophils


Dive into the research topics of 'Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer'. Together they form a unique fingerprint.

Cite this